Advertisement

Osteoporosis International

, Volume 30, Issue 12, pp 2521–2522 | Cite as

Calcifediol or vitamin D to optimize vitamin D status: Reply to letter of M Sosas

  • R. BouillonEmail author
  • J. M. Quesada-Gomez
Letter to the Editor
  • 69 Downloads

Notes

Compliance with ethical standards

Conflict of interest

None.

References

  1. 1.
    Sosa-Henríquez M. Cholecalciferol and calcifediol for vitamin D supplementation Osteoporosis letterGoogle Scholar
  2. 2.
    Quesada-Gomez JM, Bouillon R (2018) Is calcifediol better than cholecalciferol for vitamin D supplementation? Osteoporos Int. 29:1697–1711.  https://doi.org/10.1007/s00198-018-4520-y CrossRefPubMedGoogle Scholar
  3. 3.
    Bouillon R, Marcocci C, Carmeliet G, Bikle D, White JH, Dawson-Hughes B, Lips P, Munns CF, Lazaretti-Castro M, Giustina A, Bilezikian J (2019) A skeletal and extraskeletal actions of vitamin D: current evidence and outstanding questions. Endocr Rev 40(4):1109–1151.  https://doi.org/10.1210/er.2018-00126 CrossRefGoogle Scholar
  4. 4.
    Rizzoli R, Branco J, Brandi ML, Boonen S, Bruyère O, Cacoub P, Cooper C, Diez-Perez A, Duder J, Fielding RA, Harvey NC, Hiligsmann M, Kanis JA, Petermans J, Ringe JD, Tsouderos Y, Weinman J, Reginster JY (2014) Management of osteoporosis of the oldest old. Osteoporos Int. 25:2507–2529.  https://doi.org/10.1007/s00198-014-2755-9 CrossRefPubMedGoogle Scholar
  5. 5.
    Roizen JD, Long C, Casella A, O’Lear L, Caplan I, Lai M, Sasson I, Singh R, Makowski AJ, Simmons R, Levine MA (2019) Obesity decreases hepatic 25-hydroxylase activity causing low serum 25-hydroxyvitamin D. J Bone Miner Res 34:1068–1073.  https://doi.org/10.1002/jbmr.3686 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Aatsinki SM, Elkhwanky MS, Kummu O, Karpale M, Buler M, Viitala P, Rinne V, Mutikainen M, Tavi P, Franko A, Wiesner RJ, Chambers KT, Finck BN, Hakkola J (2019) Fasting-induced transcription factors repress vitamin D bioactivation, a mechanism for vitamin D deficiency in diabetes. Diabetes 68:918–931.  https://doi.org/10.2337/db18-1050 CrossRefPubMedGoogle Scholar
  7. 7.
    Bouillon R and Bikle D (2019) Vitamin D metabolism revised: fall of dogmas. J Bone Mineral Research, in pressGoogle Scholar
  8. 8.
    Burt LA, Billington EO, Rose MS, Raymond DA, Hanley DA, Boyd SK (2019) Effect of high-dose vitamin D supplementation on volumetric bone density and bone strength: a randomized clinical trial. JAMA 322:736–745.  https://doi.org/10.1001/jama.2019.11889 CrossRefPubMedGoogle Scholar
  9. 9.
    Gallagher JC (2016) Vitamin D and falls - the dosage conundrum. Nat Rev Endocrinol 12:680–684.  https://doi.org/10.1038/nrendo.2016.123 CrossRefPubMedGoogle Scholar
  10. 10.
    Bischoff-Ferrari HA, Dawson-Hughes B, Orav EJ, Staehelin HB, Meyer OW, Theiler R, Dick W, Willett WC, Egli A (2016) Monthly high-dose vitamin D treatment for the prevention of functional decline: a randomized clinical trial. JAMA Intern Med. 176:175–183.  https://doi.org/10.1001/jamainternmed.2015.7148 CrossRefPubMedGoogle Scholar
  11. 11.
    Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D, Nicholson GC (2010) Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 303:1815–1822.  https://doi.org/10.1001/jama.2010.594 CrossRefPubMedGoogle Scholar
  12. 12.
    Molin A, Wiedemann A, Demers N, Kaufmann M, Do Cao J, Mainard L, Dousset B, Journeau P, Abeguile G, Coudray N, Mittre H, Richard N, Weryha G, Sorlin A, Jones G, Kottler ML, Feillet F (2017) Vitamin D-dependent rickets type 1B (25-hydroxylase deficiency): a rare condition or a misdiagnosed condition? J Bone Miner Res 32:1893–1899.  https://doi.org/10.1002/jbmr.3181 CrossRefPubMedGoogle Scholar
  13. 13.
    Barry EL, Rees JR, Peacock JL, Mott LA, Amos CI, Bostick RM, Figueiredo JC, Ahnen DJ, Bresalier RS, Burke CA, Baron JA (2014) Genetic variants in CYP2R1, CYP24A1, and VDR modify the efficacy of vitamin D3 supplementation for increasing serum 25-hydroxyvitamin D levels in a randomized controlled trial. J Clin Endocrinol Metab. 99:E2133–E2137.  https://doi.org/10.1210/jc.2014-1389 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Zhou Y, Zhao LJ, Xu X, Ye A, Travers-Gustafson D, Zhou B, Wang HW, Zhang W, Lee Hamm L, Deng HW, Recker RR, Lappe JM (2014) DNA methylation levels of CYP2R1 and CYP24A1 predict vitamin D response variation. J. Steroid Biochem Mol Biol 144:207–214.  https://doi.org/10.1016/j.jsbmb.2013.10.004 CrossRefGoogle Scholar
  15. 15.
    Brancatella A, Cappellani D, Vignali E, Canale D, Calcifediol MC (2017) Rather than cholecalciferol for a patient submitted to malabsortive bariatric surgery: a case report. J Endocr Soc 8:1079–1084CrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2019

Authors and Affiliations

  1. 1.Department of Chronic Diseases, Metabolism and Ageing, Laboratory of Clinical and Experimental EndocrinologyKU LeuvenLeuvenBelgium
  2. 2.Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC) & Unidad de Gestión Clínica (UGC) de Endocrinología y Nutrición, Hospital Universitario Reina SofíaUniversidad de CórdobaCórdobaSpain

Personalised recommendations